AKO003 / Core One Labs - LARVOL DELTA

Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development (GlobeNewswire) - "Core One Labs Inc....is pleased to announce that...Akome Biotech Ltd. ('Akome') has initiated the next step in their clinical development designs for the use of their patent pending psychedelic formulations AKO001 and AKO003, in the treatment of ischemic stroke and depression, respectively....Akome is completing a comprehensive search and rigorous selection process, through which multiple commercial research organizations and academic centers are vetted, to determine a candidate organization to conduct the necessary in vitro and in vivo studies. Once a partner organization is chosen for both the in vivo and in vitro processes, studies can be conducted simultaneously to expedite the process."

Preclinical • CNS Disorders • Depression

Core One Labs’ Akome Biotech Protects New AKO003 Ketamine-Based Breakthrough Drug Formulation For Depression Treatment (GlobeNewswire) - "Core One Labs Inc...announce that its wholly owned subsidiary Akome Biotech Ltd. ('Akome') has protected its breakthrough ketamine psychedelic drug formulation for the treatment of Depression and is set to begin further development. The formulation of Akome’s breakthrough depression treatment, also known as AKO003, has now been developed and a provisional matter of composition patent application for AKO003 has been filed with the United States Patent and Trademark Office (USPTO) under application 63128302."

Patent • CNS Disorders • Depression • Major Depressive Disorder